Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19
Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest head...
